NCT02601313 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 68
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 92
- units
- Participants
- groups
- description
- Participants with relapsed/refractory MCL received CTE consisting of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day IV infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10\^6 anti-CD19 CAR T cells/kg on Day 0.
- id
- BG000
- title
- 2 x 10^6 Axicabtagene Ciloleucel
- description
- Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.
- id
- BG001
- title
- Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel
- description
- Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.
- id
- BG002
- title
- Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 44
- title
- < 65 years
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 48
- title
- >= 65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 15
- title
- Female
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 77
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 13
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 76
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 62
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 85
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 5
- title
- Others
- title
- Race
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 62
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 86
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Germany
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- The Safety Analysis Set included all participants treated with any dose of anti-CD19 CAR T cells.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 68
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 92
- units
- Participants
- groups
- description
- Participants with relapsed/refractory MCL received CTE consisting of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day IV infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10\^6 anti-CD19 CAR T cells/kg on Day 0.
- id
- BG000
- title
- 2 x 10^6 Axicabtagene Ciloleucel
- description
- Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 2 x 10\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 2 x 10\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.
- id
- BG001
- title
- Cohort 1: 2 x 10^6 Brexucabtagene Autoleucel
- description
- Participants with relapsed/refractory MCL received conditioning chemotherapy consisting of fludarabine 30 mg/m\^2/day and cyclophosphamide 500 mg/m\^2/day IV infusion for 3 days followed by a single infusion of brexucabtagene autoleucel at a targeted dose of 0.5 x 10\^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10\^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0.
- id
- BG002
- title
- Cohort 2: 0.5 x 10^6 Brexucabtagene Autoleucel
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 29
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 44
- title
- < 65 years
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 39
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 48
- title
- >= 65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Customized
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 15
- title
- Female
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 57
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 77
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 13
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 55
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 76
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 62
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 85
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Native Hawaiian or other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 5
- title
- Others
- title
- Race
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 62
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 86
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Germany
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- population Description
- The Safety Analysis Set included all participants treated with any dose of anti-CD19 CAR T cells.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle